strong for IL-12, although less so for IFN-γ, and the key molecules were overexpressed in diseased human tissue 1 . The failure of fontoluzimab and ustekinumab in clinical trials is therefore surprising and saddening. Yet it raises the issue as to whether blocking soluble cytokines is even worth pursuing in IBD.
These disappointing data are in line with a trend in clinical trials in IBD-nothing ever beats Remicade. All antibodies to TNF-α neutralize TNF-α, but Remicade and Humira have the added advantage that they also kill T cells and macrophages expressing membrane TNF-α, so they effectively deplete inflammatory cells. In addition, after binding membrane TNF-α, the drugs also block the production of other inflammatory cytokines such as IL-1β and IL-6 (ref. 9 ).
Agents such as Cimzia, a pegylated Fab 2 that also blocks TNF-α, have shown positive results in clinical trials; overall, however, in my opinion, they seem not quite as effective as Remicade. Although Cimzia inhibits proinflammatory cytokine production, it does not deplete cells. Likewise, neutralization of IL-6, another cytokine shown to be involved in Crohn's disease 10 , was also not particularly effective 11 and now seems to have been abandoned. The general conclusion is that redundancy in the soluble cytokine pathways that maintain activated T cells in the gut in Crohn's disease, and the myriad of effector molecules damaging the gut, may make the targeting of a single soluble molecule a fruitless effort in people with Crohn's disease (Fig. 1) . Unfortunately, this may mean reconsidering the use of mouse models of colitis in which many studies show inhibition of soluble cytokines to be a highly effective therapy 12 . Indeed, it is remarkable that so many diverse interventions worked in mice. This suggests that mucosal inflammation is so complex that any change in cytokine activity could have a positive effect in mice yet might not translate into clinical effectiveness in humans.
The real lesson from the bedside to the bench-in light of the failure of fontoluzimab and ustekinumab in the treatment of Crohn's disease and alongside the success of infliximab and Humira-is that, to have a real effect, you have to kill or disable the enemy in the gut wall, the T cells and macrophages that cause IBD. The success of therapies with antibodies to TNF-α did not show that neutralizing cytokines can be therapeutic in IBD; instead, it showed that if you kill or disable the origin of such cytokines, the proinflammatory cells, the disease may go away.
Nevertheless, why Humira and Remicade only work in 50% of people with Crohn's disease will still require further investigation, as, in reality, very little is known about the interactions between therapeutic antibodies and immune cells in the inflamed human gut.
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The author declares no competing financial interests. There is now a general consensus that the two major inflammatory bowel diseases (IBDs), Crohn's disease and ulcerative colitis, arise from an abnormal immune response to one or more bacterial components of the very rich community of commensal flora in the large bowel and the more distal parts of the small bowel 1 . Theoretically, this abnormal response can have two origins: an increased proinflammatory response to a bacterial component or a decreased regulatory response, which may lead to an excessive effector immune that promote regulatory responses, such as B. fragilis; however, the analyses conducted so far have shown that such losses usually involve large groups of organisms rather than specific bacterial strains. A surprising aspect of the B. fragilis studies was that a specific antigen such as PSA has a remarkable ability to induce Foxp3 + T reg cells. Induction of T reg cells was absent in Toll-like receptor 2 (TLR2)-deficient mice, implying that induction is due to an innate immune response mediated by TLR2. This finding suggests that PSA has a dual function-it stimulates T cells via conventional presentation to the T cell receptor, which then upregulates T cell expression of TLR2 and allows direct PSA stimulation of naive T cells that results in T reg cell differentiation.
Regardless of the mechanism, it is apparent that this polysaccharide could be the basis of a viable IBD therapy. Yet at least two questions must be answered to prove the feasibility of this approach. First, it was shown that PSA not only induces regulatory T cells that protect from IBD but also induces CD4 + T cells to undergo differentiation into IFN-γ-producing cells-T H 1 differentiation-which are potentially proinflammatory T cells 12 . As yet, the conditions that elicit a particular arm of this dichotomous response have not been defined, and it is therefore possible that, in tion of F. prausnitzii or a supernatant derived from this organism decreased the severity of TNBS-induced colitis and associated production of proinflammatory cytokines 5 . This organism, similarly to B. fragilis, can inhibit gut inflammation, although in this case the inhibitory mechanism is far less clear.
Other studies of single organisms, however, have shown that a subset of people with Crohn's disease harbor a potentially proinflammatory 'adherent-invasive' strain of Escherichia coli in their small intestine 6 . Although this has been verified by other studies, it remains unclear whether these organisms cause disease or colonize the gut after disease is established 7 .
Studies of organisms in IBD focusing on the bacterial community as a whole comprise the major effort now underway to define the gut microbiome in humans in general and in IBD in particular. Analyses of bacterial 16S rRNA by microarray probes or studies using sequencing of 16S rRNA in clonal libraries derived from bacteria, among other techniques [8] [9] [10] [11] , showed how individuals with IBD present with depletion of some commensal microbes in the phylogenic divisions Firmicutes and Bacteroidetes, including F. prausnitzii and B. fragilis, respectively 5, 8, 11 . This finding is congruent with the idea that Crohn's disease is due to or aggravated by the loss of bacteria response. In this context, IBD research has recently focused on identifying organisms or components in the gut microflora that facilitate or thwart one of these disease mechanisms.
Previous studies 2, 3 were crucial for showing how a particular gut commensal organism, Bacteroides fragilis, which expresses a capsular polysaccharide known as polysaccharide A (PSA), induces an increased immunoregulatory-and protective-response in the colons of normal mice, which is able to lessen colonic inflammation. These studies therefore pointed to a possible way of using this organism, or, more likely, a product of this organism, to treat IBD.
A recent study by Round et al. 4 represents the leading edge of this line of research. The authors showed that monocolonization of germ-free mice with B. fragilis induces accumulation of Foxp3 + regulatory cells (T reg cells) in the lamina propria in the gut, which produce increased amounts of anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor-β2 (TGF-β2) 4 . This effect was entirely dependent on the expression of PSA, as B. fragilis lacking PSA did not have the same inducing effect, and oral administration of PSA in mice resulted in an increased number of T reg cells.
Round et al. 4 also showed that T reg cells from PSA-treated mice compared to those from saline-treated mice show a PSA-specific profile with an enhanced capacity to suppress effector T cells in vitro and to express increased levels of Il-10, TGF-β2, granzyme B and CCR6 mRNA. Finally, the authors investigated the possible clinical applicability of these findings, assessing the capacity of PSA to prevent or 'cure' 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in wild-type BALB/c mice-an acute and intense T helper type 1 (T H 1) T cell (interferon-γ (IFN-γ) )-mediated colitis-by oral PSA administration either before the onset of colitis or after inflammation had been established 4 . Oral PSA administration indeed ameliorated-but did not completely reverse-colitis under both conditions, probably by increasing the number of T reg cells and their anti-inflammatory cytokines, IL-10 and TGF-β (Fig. 1) .
This study of B. fragilis 4 is part of a large group of studies that are attempting to define pro-or anti-inflammatory organisms in IBD. Studies focusing on single organisms have shown that Faecalibacterium prausnitzii has a protective function, as a reduced number of these bacteria in the intestine was associated with increased post-operative recurrence of Crohn's disease 5 . In addition, oral administra- response induced by PSA, unless the protective T reg cells completely quell an incipient inflammation and prevent countervailing secretion of inhibitory cytokines such as IL-6, a condition not met in the TNBS-induced colitis study discussed above. It might therefore be prudent to initially test the efficacy of PSA in people who are close to complete remission from disease as a result of previous treatment by surgery or administration of antibodies against inflammatory cytokines, such as antibody to TNF-α or antibody to IL-12 p40, to determine whether treatment with PSA prevents recurrent disease. This approach would obviate problems derived from the presence of cytokines that facilitate PSA induction of T H 1 cells or the presence of cytokines that inhibit T reg cell expansion or activity. some circumstances, PSA administration will induce a proinflammatory T H 1 response, which can exacerbate a preexisting inflammatory disease.
The second question relates to the general idea that induction of T reg cells can treat inflammatory disease. There is now considerable evidence that proinflammatory factors, such as IL-23, which is secreted by APCs in support of T H 17 responses, have specific downregulatory effects on T reg cell development 13 . In addition, T reg cells are considered 'plastic' , as they can convert into proinflammatory IL-17-secreting cells when they are exposed to IL-6, a cytokine secreted by inflammatory macrophages 14 .
These facts pose the possibility that robust inflammation, such as that present in IBD, can 'trump' an anti-inflammatory T reg cell
